Would you like to save this topic, event, protocol or job so you can find it again easily?
Just click the "Save to My Lab Drawer" link and the item will be saved in the My Lab Drawer
section of your bench space.
Available to members only. Please log in or register
for your free account now.
Modeling Human Malignancy with Patient-Derived Xenograft Cancer Models
Jul 26, 2012 - Jul 26, 2012
Event Type: Webinar
Registration Deadline: Jul 24, 2012
Abstract Submission Deadline: None
Description of event:
Webinar: Modeling Human Malignancy with Patient-Derived Xenograft Cancer Models
Wednesday, July 26, 1:00 PM (ET in US)
Patient-derived xenograft (PDX) cancer models show great promise as preclinical models because they reflect the diversity of human cancers seen in the clinic. The Jackson Laboratory’s PDX program was developed in collaboration with renowned cancer hospitals to advance the course of preclinical drug development. Join our technical information scientists Drs. Andrew Schile and Sheri Kuslak-Meyer and
· Learn how more than 100 “all comers” PDX models have been established in partnership with a consortium of cancer hospitals and clinical trial teams
· Appreciate how the diversity of the PDX program represents current patient demographics
· See how the genetics, pathology, and treatment response of PDX tumors reflect clinical observations
· Understand how patient-derived hematological cancers are modeled in the mouse
· Learn about current advances that take advantage of the immunodeficient NSG mouse host
· Understand how to access PDX models through JAX In Vivo Pharmacology Services
Register for this free webinar today at www.jax.org/jaxmice/news/2012/pdxWebinarJuly